Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
27 Feb, 20:00
NYSE NYSE
$
1,052. 20
+30.18
+2.95%
$
970.55B Market Cap
104.2 P/E Ratio
6% Div Yield
2,455,171 Volume
6.64 Eps
$ 1,022.02
Previous Close
Day Range
1,017.36 1,052.83
Year Range
623.78 1,133.95
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
LLY earnings report is expected in 59 days (29 Apr 2026)
Is Merck Stock Undervalued After Its Colossal Earnings Growth?

Is Merck Stock Undervalued After Its Colossal Earnings Growth?

Merck & Co., Inc. NYSE: MRK is one of the largest pharmaceutical firms in the world. The firm ranks fourth behind giants like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO, with a market capitalization of $294 billion.

Marketbeat | 1 year ago
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals

Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals

Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.

Zacks | 1 year ago
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed

Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed

When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower.

Benzinga | 1 year ago
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits

Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.

Reuters | 1 year ago
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem

This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem

Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the revenue potential of these drugs.

Fool | 1 year ago
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock

Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock

Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.

Cnbc | 1 year ago
Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 5, 2024 7:45 AM ET Company Participants Jacob Van Naarden - Executive Vice President & President of Lilly Oncology Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Good morning, everybody.

Seekingalpha | 1 year ago
Eli Lilly's weekly insulin intensifies race with Novo Nordisk

Eli Lilly's weekly insulin intensifies race with Novo Nordisk

A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company's race with Novo Nordisk to develop longer-acting insulins.

Marketwatch | 1 year ago
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.

Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.

As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound.

Fool | 1 year ago
Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?

Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 year ago
Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points

Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points

Power Inflow occurred at 10:31 am at 958.10. The stock rose to 965.94 at 11:37 am.

Benzinga | 1 year ago
Loading...
Load More